This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.
≥18 years old
Histologically confirmed SBP with <10% clonal plasma cells in marrow
ECOG ≤ 2
No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion.
Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy.
Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.